IUPAC/Chemical Name
Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5alpha,6alpha)-
InChi Key
NETZHAKZCGBWSS-RLVOKJKJSA-N
InChi Code
InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16-,19+,20+,21-/m1/s1
SMILES Code
OC1=CC=C2C[C@@H](N(CC3CCC3)CC4)[C@]5(O)CC[C@@H](O)[C@@]6([H])[C@]54C2=C1O6
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
357.45
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Jannuzzi RG. Nalbuphine for Treatment of Opioid-induced Pruritus: A Systematic Review of Literature. Clin J Pain. 2016 Jan;32(1):87-93. doi: 10.1097/AJP.0000000000000211. PMID: 26650717.
2: Davis MP, Fernandez C, Regel S, McPherson ML. Does nalbuphine have a niche in managing pain? J Opioid Manag. 2018 Mar/Apr;14(2):143-151. doi: 10.5055/jom.2018.0441. PMID: 29733100.
3: Reiter PD, Clevenger AC. Nalbuphine Reduces Opioid-Associated Urinary Retention in Pediatric Patients. Pediatr Crit Care Med. 2019 May;20(5):e240-e244. doi: 10.1097/PCC.0000000000001920. PMID: 31013261.
4: Deng C, Wang X, Zhu Q, Kang Y, Yang J, Wang H. Comparison of nalbuphine and sufentanil for colonoscopy: A randomized controlled trial. PLoS One. 2017 Dec 12;12(12):e0188901. doi: 10.1371/journal.pone.0188901. PMID: 29232379; PMCID: PMC5726642.
5: Kubica-Cielińska A, Zielińska M. The use of nalbuphine in paediatric anaesthesia. Anaesthesiol Intensive Ther. 2015;47(3):252-6. doi: 10.5603/AIT.2015.0036. PMID: 26165241.
6: Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG. Nalbuphine. Drug Alcohol Depend. 1985 Feb;14(3-4):339-62. doi: 10.1016/0376-8716(85)90066-3. PMID: 2986929.
7: Liang RJ, Shih YN, Chen YL, Liu WY, Yang WL, Lee SY, Wang HJ. A dual system platform for drug metabolism: Nalbuphine as a model compound. Eur J Pharm Sci. 2020 Jan 1;141:105093. doi: 10.1016/j.ejps.2019.105093. Epub 2019 Oct 21. PMID: 31648049.
8: Inan S, Torres-Huerta A, Jensen LE, Dun NJ, Cowan A. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. Eur J Pharmacol. 2019 Dec 1;864:172702. doi: 10.1016/j.ejphar.2019.172702. Epub 2019 Sep 27. PMID: 31568781; PMCID: PMC6913640.
9: Narver HL. Nalbuphine, a non-controlled opioid analgesic, and its potential use in research mice. Lab Anim (NY). 2015 Mar;44(3):106-10. doi: 10.1038/laban.701. PMID: 25693108.
10: Schultz-Machata AM, Becke K, Weiss M. Nalbuphin in der Kinderanästhesie [Nalbuphine in pediatric anesthesia]. Anaesthesist. 2014 Feb;63(2):135-43. German. doi: 10.1007/s00101-014-2293-z. PMID: 24504192.
